Clinical trials: Lymphoma, Non-Hodgkin
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.
- Trial name
- NCT04034446
- Testing
- CD19-CD22 CAR-T cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Acute Lymphoblastic Leukemia
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride
- Trial name
- NCT00289562
- Testing
- forodesine hydrochloride (BCX-1777)
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- BioCryst Pharmaceuticals
Diffuse Large B-Cell Lymphoma
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
This is a randomised, double-blind, positive drug parallel controlled equivalence clinical trial initiated at about 30 sites in China.
- Trial name
- NCT04361279
- Testing
- SIBP-02, Rituximab
- Where
- China
- Volunteers
- 421 people
- Sponsor
- Shanghai Institute Of Biological Products
Peripheral T Cell Lymphoma
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the alternative salvage regimens.
- Trial name
- T-START-NR (NCT07470996)
- Testing
- Allogenic stem cell transplant (ASCT), Salvage Therapy
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Conditions
- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT05828589
- Testing
- BGB-21447
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 51 people
- Sponsor
- BeOne Medicines
Diffuse Large B Cell Lymphoma
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.
- Trial name
- R-CHOEP-brut (NCT03399513)
- Testing
- Ibrutinib Oral Capsule [Imbruvica], R-CHOEP chemotherapy
- Where
- 12 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Muenster
Non-Hodgkin's Lymphoma
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks.
- Trial name
- NCT00712582
- Testing
- Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered in routine clinical care.
- Trial name
- RE-MIND2 (NCT04697160)
- Where
- 165 sites in United States, Australia and 10 more
- Volunteers
- 3,573 people
- Sponsor
- MorphoSys AG
Diffuse Large B Cell Lymphoma
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r DLBCL who received CD19 CAR-T therapy.
- Trial name
- NCT04316624
- Testing
- C-CAR066
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT03583424
- Testing
- Carmustine, Cytarabine, Etoposide
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lymphoma, Neuroblastoma
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
RATIONALE: New imaging procedures, such as whole-body MRI, may improve the ability to detect metastatic cancer and determine the extent of disease.
- Conditions
- Lymphoma, Neuroblastoma, Sarcoma
- Trial name
- NCT00072488
- Testing
- computed tomography, magnetic resonance imaging, positron emission tomography
- Where
- 21 sites in United States, Canada
- Volunteers
- 226 people
- Sponsor
- American College of Radiology Imaging Network
Lymphoma, Non-Hodgkin
High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas
Central nervous system (CNS) relapses of aggressive lymphomas are a rare but devastating complication. There is no therapy standard, conventional approaches are palliative.
- Trial name
- NCT01148173
- Testing
- Combined systemic and intrathecal chemotherapy followed by HD-ASCT
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Non-hodgkin's Lymphoma
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma
This study is a multicenter, non randomized, single arm, open clinical trial. The selected disease was relapsed / refractory NHL, and the disease was classified into highly aggressive lymphoma, invasive lymphoma and inert…
- Trial name
- NCT04666168
- Testing
- Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
HIV, Organ Transplantation
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Despite the greater risk of adverse COVID-19 outcomes, antibody and cell-mediated immune responses to COVID-19 vaccines vary amongst immunocompromised (IC) people and are poorly defined.
- Conditions
- HIV, Organ Transplantation, Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
- Trial name
- BOOST-IC (NCT05556720)
- Testing
- Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA vaccine
- Where
- 13 sites in Australia
- Volunteers
- 960 people
- Sponsor
- Monash University
B-Cell Prolymphocytic Leukemia, Hypodiploidy
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic…
- Conditions
- B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia
- Trial name
- NCT01008462
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003262
- Testing
- bleomycin sulfate, filgrastim, Stanford V regimen
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Adult
- Trial name
- NCT03260101
- Testing
- non intervational
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Cellect Biotechnology
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
This study evaluates the addition of Sintilimab to current 2nd line salvage therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04659434
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Qian Wenbin
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Phase IIa study to estimate the efficacy of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as CART-19 or CTL019…
- Trial name
- NCT02030834
- Testing
- CART-19
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.